EXEL
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think “Yes”
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Read moreDetails
Exelixis Posts 63.7% Profit Surge
Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise...
Read moreDetails
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.
Read moreDetails
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We...
Read moreDetails
EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY)....
Read moreDetails